In Celexir’s body-recomposition toolkit, Follistatin 344 is positioned for highly selective use where rapid lean-mass support and anti-catabolic protection are clinical priorities—e.g., extreme deconditioning or rehabilitative contexts under close supervision. Catalog guidance frames it for muscle growth support, prevention of muscle wasting, and lean-mass enhancement, supplied in ready-to-use formats with GMP documentation to keep dosing and handling consistent.
How it works: Follistatin binds and neutralizes myostatin (and related activins), lifting the physiologic “brake” on muscle hypertrophy and promoting satellite-cell activation—a mechanism widely validated in preclinical literature on myostatin pathway inhibition.
Evidence & diligence: Human evidence for peptide-based Follistatin 344 remains limited; most clinical translation to date centers on gene-therapy approaches or other myostatin-pathway agents, with mixed results across neuromuscular indications. Clinicians should treat Follistatin 344 as investigational, use informed consent, and track objective outcomes (strength, lean mass, function). Note that myostatin-pathway agents including follistatin are prohibited by WADA for sport, and there is no FDA approval for this peptide in muscle growth or fat-loss indications.
Celexir delivery & specs: typical catalog protocol 100–300 mcg/day in short cycles; >98% purity (HPLC-validated); 2–8 °C storage; CoA/MSDS provided; prefilled pen or lyophilized vial to streamline clinical workflow from warehouse to administration. Integrate within comprehensive programs—protein sufficiency, resistance training progression, sleep, and metabolic control—to translate signaling into durable, real-world strength and function.